New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Treatment Groups and Common Treatment Regimens | Download Scientific Diagram
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
PDF) Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
1 Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelO
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
The role of MRD in CLL
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting | SpringerLink
Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
The role of MRD in CLL
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de